PD-L1 or PD-1 monoclonal antibodies, known as immune checkpoint inhibitors, have been employed in the treatment of various types of malignancies, including melanoma, non-small cell lung cancer, gastric cancer, and breast cancer [56–59]. The gene discussed is PDCD1; the disease is breast carcinoma.